86% of Intuitive Surgical's revenue is recurring. The robot itself is basically the loss leader.

Intuitive Surgical makes the da Vinci robotic surgical system, along with the Ion platform for lung procedures. Surgeons control robotic arms to perform minimally invasive surgery with more precision and smaller incisions than traditional techniques allow. The company pioneered this category and still dominates it decades later.

The business model is the actual story here. Selling or leasing the robot itself isn't where the real money is. Every procedure performed on a da Vinci system requires new instruments and accessories, and those get repurchased continuously as hospitals keep using the machine. In Q1 2026, instruments and accessories revenue made up the majority of total revenue and grew 23% year over year, roughly in line with procedure volume growth. Recurring revenue overall made up 86% of total revenue in Q1. Once a hospital buys a multi-million dollar robot and trains its surgeons on it, switching to a competing platform is a genuinely difficult, expensive decision, which is exactly what makes the recurring revenue so durable.

The installed base keeps expanding too: 11,710 da Vinci systems worldwide as of Q2 2026, up 12% year over year, with the newer da Vinci 5 platform running about 11% higher utilization than the previous generation Xi system. Q1 revenue was $2.77 billion, up 23%, and Q2 came in at $2.89 billion, up 19%, with non-GAAP EPS nearly doubling from $2.19 to $2.80 year over year in Q2 alone.

Here's the part that genuinely surprised me. Despite that strong Q2 beat, the stock fell about 10% after hours because management kept full-year da Vinci procedure growth guidance unchanged at 13.5-15.5%, rather than raising it again like they had after Q1. That would represent the company's slowest procedure growth in several years, and the market read "no raise" as a red flag even with double-digit growth and margin expansion sitting right there in the actual results.

The real risks with Intuitive Surgical are genuine: China and Japan are seeing slower growth from lower tender activity and domestic competition, US bariatric procedures actually declined about 10% as GLP-1 drugs reduce demand for weight-loss surgery, and rising memory and tariff costs are pressuring gross margins for the rest of the year. The stock trades at 44x forward earnings, below its own decade-long average multiple, which some read as a genuine value opportunity in a durable moat business, and others see as fair given the growth deceleration. Anyone holding through the guidance disappointment?